Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company, has a lead program entering Phase 3 for hypertriglyceridemia. The company’s cardiovascular programs take advantage of the staff’s expertise in the field of lipid science and the acknowledged therapeutic benefits of essential fatty acids in cardiovascular disease. In addition to Amarin’s lead program, their pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease and epilepsy. For further information, visit the Company’s web site at www.amarincorp.com.
- 18 years ago
QualityStocks
Amarin Corporation plc (NASDAQ: AMRN)
Related Post
-
Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments
In the United States alone, close to one million people are living with MS, with…
-
Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step
California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…
-
Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership
The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…